1. Scoring the Value Assessment Framework for China: A Factorial Survey.
- Author
-
Zhang, Mengmeng, Yang, Yi, Bao, Yun, Kimber, Melissa, Levine, Mitchell, and Xie, Feng
- Subjects
- *
VALUE (Economics) , *BACHELOR'S degree , *FACTORIALS , *INSURANCE , *ECONOMIC impact , *LIFTING & carrying (Human mechanics) - Abstract
This study aimed to develop the scoring functions for the recently developed value assessment framework (VAF) for China, which comprises 12 attributes. We implemented a factorial survey among Chinese healthcare stakeholders from July to September 2022. A total of 240 hypothetical drug value profiles described by the VAF were grouped into 60 blocks and randomly assigned to respondents. Each respondent was assigned with 1 block, each presented in 3 disease scenarios of different levels of severity. For each profile, respondents were asked to assess the drug's value on a scale from 0 (lowest) to 10 (highest) and make 1 of the 3 insurance recommendations: cover, to be negotiated for coverage, or reject. Linear and logistic mixed-effects models were used to develop scoring functions for aggregating the value attributes. A total of 365 respondents participated in the survey. 3968 responses from 331 respondents were included in the analysis. Most of the included respondents were under 45 (n = 256, 77.3%), females (n = 208, 62.8%), living in urban areas (n = 296, 89.4%), and with a bachelor's degree or higher (n = 303, 91.5%). Health benefits and safety carried more weights than other attributes in the scoring functions across disease scenarios. The value and probability of entering negotiation or receiving insurance coverage for the attribute profiles for severe/critical disease were higher than for mild/moderate disease. The scoring functions of the VAF can be used to assess the value of a drug and its probability of entering negotiation or receiving insurance coverage in China. • Through qualitative interviews and document analysis, 12 attributes grouped in 8 categories were identified and included in a value assessment framework for China. The value assessment framework comprises severity of disease, health benefits, safety, economic impact, innovation, organizational impact, health equity, and quality of evidence. • We conducted a factorial survey in which 240 value profiles with 10 attributes experimentally varying in their levels were randomly assigned to 365 healthcare stakeholders in China to assess the value of hypothetical drugs and make insurance coverage recommendations. • The scoring functions can be used to estimate the value of a drug and the probability of its entering negotiation or receiving coverage in China in different disease scenarios. In the scoring functions for severe/critical disease or mild/moderate disease, health benefits and safety carried higher weights than other attributes. The value and probability of entering negotiation or receiving insurance coverage are higher for attribute profiles for severe/critical disease than for mild/moderate disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF